Experimental and clinical pharmacology of ultra low doses of antibodies

Biological properties of ultra-low doses of antibodies to endogenous regulators of functions were revealed and evaluated in the study. Drugs containing ultra-low doses of antibodies were developed; they proved to be highly effective and low- toxic. Preclinical studies demonstrated the efficacy of ultra-low doses of antibodies in the treatment of experimental pathologies in animals that is comparable with standard comparators; besides no adverse events were registered. Studies of toxicity proved that novel drugs are highly safe and non toxic. The efficacy and safety of these drugs were confirmed in clinical studies.